Gene Editing
STAT+: FDA approves Reata’s treatment for rare neurological disease
The Food and Drug Administration on Tuesday approved the first drug to treat Friedreich’s Ataxia, a rare, neurological disease.
The new drug, called Skyclarys, is made by Reata Pharmaceuticals.
